[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP3784672A4 - Formulations de comprimés comprenant de la metformine et de la sitagliptine - Google Patents

Formulations de comprimés comprenant de la metformine et de la sitagliptine Download PDF

Info

Publication number
EP3784672A4
EP3784672A4 EP19834733.8A EP19834733A EP3784672A4 EP 3784672 A4 EP3784672 A4 EP 3784672A4 EP 19834733 A EP19834733 A EP 19834733A EP 3784672 A4 EP3784672 A4 EP 3784672A4
Authority
EP
European Patent Office
Prior art keywords
sitagliptin
metformin
tablet formulations
formulations
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19834733.8A
Other languages
German (de)
English (en)
Other versions
EP3784672A2 (fr
Inventor
Ali Turkyilmaz
Seval Ataman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP3784672A2 publication Critical patent/EP3784672A2/fr
Publication of EP3784672A4 publication Critical patent/EP3784672A4/fr
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP19834733.8A 2018-04-27 2019-03-25 Formulations de comprimés comprenant de la metformine et de la sitagliptine Pending EP3784672A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201806019 2018-04-27
PCT/TR2019/050190 WO2020013777A2 (fr) 2018-04-27 2019-03-25 Formulations de comprimés comprenant de la metformine et de la sitagliptine

Publications (2)

Publication Number Publication Date
EP3784672A2 EP3784672A2 (fr) 2021-03-03
EP3784672A4 true EP3784672A4 (fr) 2022-03-30

Family

ID=69141601

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19834733.8A Pending EP3784672A4 (fr) 2018-04-27 2019-03-25 Formulations de comprimés comprenant de la metformine et de la sitagliptine

Country Status (2)

Country Link
EP (1) EP3784672A4 (fr)
WO (1) WO2020013777A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022074664A1 (fr) * 2020-10-05 2022-04-14 V-Ensure Pharma Technologies Private Limited Composition à libération immédiate de chlorhydrate de sitagliptine
KR20230009020A (ko) * 2021-07-08 2023-01-17 한미약품 주식회사 시타글립틴, 다파글리플로진 및 메트포르민을 포함하는 경구용 복합정제
CN114010612B (zh) * 2021-11-24 2022-06-28 上海普康药业有限公司 一种西格列汀二甲双胍双层缓释片及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100323011A1 (en) * 2008-03-04 2010-12-23 Nazaneen Pourkavoos Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
EP3731828A2 (fr) * 2017-12-28 2020-11-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Formulations de comprimés comprenant de la metformine et de la sitagliptine traitées par extrusion à chaud

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
PE20140923A1 (es) 2007-07-19 2014-08-11 Takeda Pharmaceutical Preparacion solida que comprende alogliptina y clorhidrato de metformina
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
WO2013110085A1 (fr) * 2012-01-20 2013-07-25 Handa Pharmaceuticals, Llc Formes pharmaceutiques destinées à l'administration par voie orale de metformine et de sitagliptine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100323011A1 (en) * 2008-03-04 2010-12-23 Nazaneen Pourkavoos Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
EP3731828A2 (fr) * 2017-12-28 2020-11-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Formulations de comprimés comprenant de la metformine et de la sitagliptine traitées par extrusion à chaud

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020013777A2 *

Also Published As

Publication number Publication date
EP3784672A2 (fr) 2021-03-03
WO2020013777A3 (fr) 2020-04-09
WO2020013777A2 (fr) 2020-01-16

Similar Documents

Publication Publication Date Title
EP3706741A4 (fr) Composition pharmaceutique et utilisation associée
EP3849983A4 (fr) Composés de triazolo-pyrimidine et leurs utilisations
EP3904351A4 (fr) Inhibiteur de fak et combinaison de médicaments associée
EP3802562A4 (fr) Nouvelle utilisation pharmaceutique
EP3735463A4 (fr) Agent thérapeutique induisant une cytotoxicité
EP3760632A4 (fr) Dérivé de pyrazolopyrimidine et son utilisation
EP4051246A4 (fr) Formulations de comprimés bicouches comprenant de la dapagliflozine et de la metformine
EP3981769A4 (fr) Composé de pyrrolopyrimidine et son utilisation
IL284994A (en) Pyrrolopyrimidine derivative and its use
EP3737676A4 (fr) Composés acétal et leurs utilisations thérapeutiques
EP3687501A4 (fr) Formulations d'iniparib et leurs utilisations
EP3784672A4 (fr) Formulations de comprimés comprenant de la metformine et de la sitagliptine
EP3760616A4 (fr) Composé de 4-méthyldihydropyrimidinone et son utilisation médicinale
EP3731837A4 (fr) Combinaison contenant de la linagliptine et de la metformine
EP3886820B8 (fr) Formulations de capsules
EP3697411A4 (fr) Nouvelle composition pharmaceutique et son utilisation
EP3793561A4 (fr) Composés médicamenteux antiviraux et composition associée
EP3755376A4 (fr) Formulations contenant des protéases affectant la mucine
EP3716766A4 (fr) Composés de benzoxaborole et leurs formulations
EP4031122A4 (fr) Formulations de comprimés effervescents comprenant de la dapagliflozine et de la metformine
EP3497080A4 (fr) Formulations pharmaceutiques et leur utilisation
EP4051270A4 (fr) Composés de 4-amino-imidazoquinoline et utilisation de ceux-ci
EP3999056A4 (fr) Combinaison pharmaceutique et son utilisation
EP3851108A4 (fr) Médicament à base de borate et utilisation associée
EP3901146A4 (fr) Composé phénylpyrrolidine et son utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201027

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07D0487040000

Ipc: A61K0009200000

A4 Supplementary search report drawn up and despatched

Effective date: 20220224

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4985 20060101ALI20220220BHEP

Ipc: A61K 31/155 20060101ALI20220220BHEP

Ipc: A61K 9/24 20060101ALI20220220BHEP

Ipc: A61K 9/20 20060101AFI20220220BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230708